Hepatitis C Virus Infection in Adolescents and Adults: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults aged 18 to 79 years The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years. B View the Clinical Summary in What does the USPSTF recommend? For adults aged 18 to 79 years: Grade B Screen adults for hepatitis C virus (HCV) infection. To whom does (...) evidence to determine how often to screen persons at increased risk. What are other relevant USPSTF recommendations? The USPSTF has made recommendations on screening for hepatitis B virus infection in pregnant persons, hepatitis B virus infection in adults, and HIV infection. These recommendations are available at . Where to read the full recommendation statement? Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the recommendation

Hepatitis E: symptoms, transmission, prevention, treatment Hepatitis E: symptoms, transmission, prevention, treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis E: symptoms, transmission, prevention, treatment The symptoms, means of transmission, best means of prevention and treatment of hepatitis E. Published 1 June 2014 Last updated 16 July 2019 — From: Documents HTML Details (...) This document explains hepatitis E, describing the: symptoms means of transmission best means of prevention and treatment Published 1 June 2014 Last updated 16 July 2019 16 July 2019 Added provisional data for January to March 2019. 8 March 2019 Updated the number of hepatitis E cases in 2017 and 2018. 7 November 2018 Added provisional data for January to September 2018. 10 August 2018 Added provisional data for January to June 2018. 1 August 2018 Updated 2017 figures. 1 February 2018 Updated number

Screening for Hepatitis C Virus Infection Screening for Hepatitis C Virus Infection | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Screening for Hepatitis C Virus Infection Practice Advisory April 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. . The on March 2, 2020. New guidance from both the CDC and the USPSTF represent a change in routine screening (...) for HCV; both organizations now recommend HCV screening for all adults, including pregnant and nonpregnant individuals. The American College of Obstetricians and Gynecologists (ACOG) is actively reviewing the new guidance from the CDC and USPSTF. Updated guidance from ACOG will be posted on ACOG’s website and published in Obstetrics & Gynecology when available. ACOG is also reviewing its current guidance on the screening and management of hepatitis for pregnant individuals in ACOG Practice Bulletin

AASLD Guidelines for Treatment of Chronic Hepatitis B Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance Norah A. Terrault, 1 Anna S.F. Lok, 2 Brian J. McMahon, 3 Kyong-Mi Chang, 4 Jessica P. Hwang, 5 Maureen M. Jonas, 6 Robert S. Brown Jr., 7 Natalie H. Bzowej, 8 and John B. Wong 9 Purpose and Scope of the Guidance This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic (...) Hepatitis B (1) and update the previous hepatitis B virus (HBV) guidelines from 2009. The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coin- fections, acute

Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV. Cases of acute HCV infection have increased approximately 3.8-fold over the last decade because of increasing

Givosiran (Givlaari) - acute hepatic porphyria Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/62114/2020 EMEA/H/C/004775 Givlaari (givosiran) An overview of Givlaari and why (...) it is authorised in the EU What is Givlaari and what is it used for? Givlaari is a medicine for treating acute hepatic porphyria in patients aged 12 years or over. Acute hepatic porphyria is a rare genetic condition in which the liver cannot properly produce a substance called haem. As a result, substances used to make haem build up in the body, causing attacks of severe abdominal pain, vomiting and nervous system disorders. Acute hepatic porphyria is rare, and Givlaari was designated an ‘orphan medicine

Toolkit to support the generation of robust estimates of hepatitis C prevalence TECHNICAL REPORT Technical protocol for hepatitis C prevalence surveys in the general population SPHERE-C Project www.ecdc.europa.euECDC TECHNICAL REPORT Technical protocol for hepatitis C prevalence surveys in the general population SPHERE-C Project ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Erika Duffell and Andrew Amato-Gauci, and produced (...) : European Centre for Disease Prevention and Control. Technical protocol for hepatitis C prevalence surveys in the general population. Stockholm: ECDC; 2020. Stockholm, February 2020 ISBN 978-92-9498-423-4 doi: 10.2900/30190 Catalogue number TQ-03-19-928-EN-N © European Centre for Disease Prevention and Control, 2019 Cover picture: © Science Photo Reproduction is authorised, provided the source is acknowledged. For any use or reproduction of photos or other material that is not under the EU copyright

Phlebotomy resulting in controlled hypovolaemia to prevent blood loss in major hepatic resections (PRICE-1): a pilot randomized clinical trial for feasibility Major liver resection is associated with blood loss and transfusion. Observational data suggest that hypovolaemic phlebotomy can reduce these risks. This feasibility RCT compared hypovolaemic phlebotomy with the standard of care, to inform a future multicentre trial.Patients undergoing major liver resections were enrolled between June

Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. To evaluate the effectiveness and cost effectiveness of a complex intervention in primary care that aims to increase uptake of hepatitis C virus (HCV) case finding and treatment.Pragmatic, two armed, practice level, cluster randomised controlled trial and economic evaluation.45 general practices in South West England (22 randomised

Disorders of the Hepatic and Mesenteric Circulation ACG Clinical Guideline: Disorders of the Hepatic and Mesente... : American Journal of Gastroenterology ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800 (...) Abstract Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries have important clinical consequences and may lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma. Although literature in the field of vascular liver disorders is scant, these disorders are common in clinical practice, and general practitioners, gastroenterologists, and hepatologists may benefit from expert guidance

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomized trial of the safety and efficacy of 12 and 16 weeks of G/P, with or without

Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation

Givosiran (Givlaari) - acute hepatic porphyria Drug Approval Package: GIVLAARI (givosiran)Injection U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GIVLAARI (givosiran)Injection Company: Alnylam Pharmaceuticals Inc. Application Number: 212194 Approval Date: 11/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files

Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations. Hepatitis C virus (HCV) disproportionately affects disadvantaged communities.To examine processes and outcomes of Screen, Treat, Or Prevent Hepatocellular Carcinoma (STOP HCC), a multicomponent intervention for HCV screening and care in safety-net primary care practices.Mixed-methods retrospective analysis.5 federally qualified health centers (FQHCs) and 1 family

Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Carfilzomib (Kyprolis▼): risk (...) of reactivation of hepatitis B virus Establish hepatitis B status before initiating carfilzomib and in patients with unknown hepatitis B virus serology who are already being treated with carfilzomib. Published 21 November 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: hepatitis B virus reactivation has been reported in patients treated with carfilzomib screen all patients for hepatitis B virus before initiation of carfilzomib; patients with unknown serology who are already

Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Glecaprevir/Pibrentasvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A19-33 Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-33 Version 1.0 Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) 11 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Glecaprevir/pibrentasvir (chronic hepatitis C

Hepatitis B: the green book, chapter 18 Hepatitis B: the green book, chapter 18 - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis B: the green book, chapter 18 Hepatitis B immunisation information (...) for public health professionals. Published 20 March 2013 Last updated 18 November 2019 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details is an infection of the liver caused by the hepatitis B virus (HBV). Published 20 March 2013 Last updated 18 November 2019 18 November 2019 Removed previous

Practice Advisory: Hepatitis B Prevention Practice Advisory: Hepatitis B Prevention - ACOG Menu ▼ Practice Advisory: Hepatitis B Prevention Page Navigation ▼ Share: Practice Advisory: Hepatitis B Prevention The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) have released updated guidance on preventing the transmission of hepatitis B virus (HBV) infection (1). A critical element of the strategy to eliminate HBV in the United States (...) is the prevention of perinatal transmission. The CDC and ACIP’s updated guidance reflects the best currently available evidence and select new or updated recommendations include the following: Pregnant women positive for hepatitis B surface antigen (HBsAg) should be tested for hepatitis B virus deoxyribonucleic acid (HBV DNA) to guide the use of antiviral medication to prevent perinatal transmission Persons with chronic liver disease* should be vaccinated against HBV The American Association for the Study

Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents Published 11 November 2019 1 Product update SMC2214 glecaprevir/pibrentasvir 100mg/40mg film-coated tablets (Maviret®) AbbVie Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated (...) submission glecaprevir/pibrentasvir (Maviret®) is accepted for use within NHSScotland. Indication under review: treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years. SMC has previously accepted glecaprevir/pibrentasvir for the treatment of chronic HCV infection in adults. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of glecaprevir/pibrentasvir. This advice is contingent upon the continuing

Hepatitis E: health protection response to reports of infection Hepatitis E: health protection response to reports of infection - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote (...) in the General Election on 12 December. Guidance Hepatitis E: health protection response to reports of infection Guidance on low public health risk, surveillance process and follow up with contacts. Published 14 June 2012 Last updated 8 November 2019 — From: Documents Ref: PHE publications gateway number: GW-698 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you